Alembic Pharmaceuticals Limited (APLLTD) reported its consolidated financial results for the second quarter and half year ended 30th September, 2026. The company delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Revenue from operations increased by 36% year-on-year to Rs. 2603 Cr. Moreover, the Profit After Tax (PAT) surged by 81% year-on-year to Rs. 335 Cr.

Operational Highlights

The India Branded Business delivered 14% year-on-year growth, reaching Rs 725 Cr. in revenue for the quarter. Gynecology, Cardiology, Gastrology, and Ophthalmology registered robust growth. Animal Health continued its growth momentum with 23% growth for the quarter.

International Business

US Formulations grew by 77% to Rs. 1003 Cr. The company also had three launches in the US market during the quarter. Ex-US grew by 12% to Rs. 440 Cr. The Active Pharmaceutical Ingredients (API) business grew by 39% to Rs. 436 Cr.

Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders.”

For more information, visit www.alembicpharmaceuticals.com or contact Isha Lamba at +91 022-66951652 or isha.lamba@alembic.co.in.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.

Marksans Pharma Limited (NSE: MARKSANS) reported financial results for Q2 and H1 FY27, marking a significant milestone with quarterly revenue crossing ₹900 crore for the first time. The company’s Q2FY27 EBITDA surged 48% to a record ₹214 crore, while H1FY27 PAT nearly doubled to ₹303 crore. Mark Saldanha, Founder, Chairman & Managing Director, highlighted the company’s strong performance, driven by broad-based growth across all regions.

Q2FY27 Highlights

In Q2FY27, Marksans Pharma’s operating revenue reached ₹940 crore, up 30.5% year-on-year (YoY). Adjusted for acquisition impact, revenue growth remained robust at 25%. EBITDA grew 48.3% to ₹214 crore, with margins expanding by 274 basis points to 22.8%. Notably, the UK & Europe market grew 64.9% to a record ₹405 crore, while the US & North America segment delivered its highest-ever quarter at ₹421 crore.

H1FY27 Performance

For H1FY27, revenue grew 32.9% to ₹1,781 crore. EBITDA rose 74.7% with margins up 574 basis points to 24.0%, and PAT nearly doubled to ₹303 crore. The company’s operating cash flow reached ₹322 crore, 4.3 times the previous year, and cash balances closed at ₹1,124 crore. Marksans Pharma’s trailing twelve-month return on capital employed (ROCE) improved to 24.7%.

Mark Saldanha emphasized the company’s expanding global footprint, robust product pipeline, and strong net-cash position. ‘We enter the next phase of our growth journey from a position of considerable strength,’ he said. ‘Our focus remains on sustaining profitable organic growth while selectively pursuing strategic acquisitions that strengthen our capabilities and market presence. We remain confident in our growth trajectory and committed to creating sustainable long-term shareholder value.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Marksans Pharma Limited

Marksans Pharma Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Marksans gains 16.4% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 16.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 1.7% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 16.7% and profits at 16.2%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Marksans Pharma Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal second quarter ended September 30, 2026. The company reported total income of Rs 4,423 crore, up 1% year-on-year (YoY). The consolidated operating revenue increased 2% YoY to Rs 4,389 crore.

Financial Performance

Biopharma revenue increased 5% YoY to Rs 3,583 crore. Biosimilars revenue increased 3% YoY to Rs 2,809 crore, while generics revenue increased 10% YoY to Rs 774 crore. Services revenue increased 13% quarter-on-quarter (QoQ) to Rs 833 crore.

Leadership Comments

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, stated, ‘Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway.’ Shreehas Tambe, CEO & Managing Director, Biocon Limited, added, ‘We are well positioned for growth in the second half of FY27, with the upcoming European launch of Pertuzumab and expanded insulin manufacturing capacity in Malaysia to support growing U.S. demand.’

As a result, Biocon Limited is confident in its long-term growth trajectory, driven by strategic milestones and continued investments in technology and innovation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.